The effect of a 5-HT3 receptor antagonist, ondansetron, on brain stimulation reward, and its interaction with direct and indirect stimulants of central dopaminergic transmission
- 1 February 1993
- journal article
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 91 (1) , 1-11
- https://doi.org/10.1007/bf01244914
Abstract
5-HT3 receptors are abundant in central dopamine (DA) terminal areas. They do not affect basal DA turnover but appear to modulate DA release by e.g. morphine and nicotine. The interpretation of these findings is uncertain, and it is unclear whether 5-HT3 receptors also influence the activity of compounds such as amphetamine and cocaine, which act more directly on the DA synapse. Variable-interval (VI), threshold-current hypothalamic self-stimulation can provide a continuous index of central dopaminergic activity, but is relatively insensitive to changes in 5-HT and thus offers a means of investigating this question. In the present study, a selective 5-HT3 receptor antagonist, ondansetron (GR 38032F) (1.0 to 1000 μg/kg sc), had no effect on VI self-stimulation, nor did a 100 μg/kg dose affect facilitation of responding byd-amphetamine (500 jig/kg ip). Ondansetron (100 μg/kg) reduced the initial depression of self-stimulation by high-dose nicotine (400 μg/kg), but not the ensuing facilitation. Similar results were obtained in rats “sensitized” to nicotine by prior chronic exposure. These results support the proposal that 5-HT3 receptors, normally quiescent under basal conditions, mediate the excitatory effect of compounds acting upstream from the DA neuron, such as nicotine, but do not affect the dopaminergic synapse directly.Keywords
This publication has 34 references indexed in Scilit:
- The effect of intraventricular administration of the 5-HT3 receptor agonist 2-methylserotonin on the release of dopamine in the nucleus accumbens: an in vivo chronocoulometric studyPublished by Elsevier ,2003
- Schedule-controlled brain self-stimulation: Has it utility for behavioral pharmacology?Neuroscience & Biobehavioral Reviews, 1992
- Effects of 5-HT3 antagonists on fixed-interval behavior in ratsPharmacology Biochemistry and Behavior, 1992
- Ondansetron in treatment of schizophreniaThe Lancet, 1991
- GR38032F, a serotonin 5-HT3 antagonist, fails to alter cocaine self-administration in ratsPharmacology Biochemistry and Behavior, 1991
- The effect of ondansetron on cognitive performance in the marmosetPharmacology Biochemistry and Behavior, 1991
- Excitatory amino acid pathways in brain-stimulation rewardBehavioural Brain Research, 1990
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990
- Identification and distribution of 5-HT3 receptors in rat brain using radioligand bindingNature, 1987
- Catecholamines and self-stimulation: Evidence suggesting a reinforcing role for noradrenaline and a motivating role for dopaminePharmacology Biochemistry and Behavior, 1976